Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OrbusNeich Medical Group HoldingsFRA:Q8T -3.47%96 Return-on-Tangible-Equity is 11.36% as of Dec. 2025, which is 3% above its 10-year median of 11.05. GuruFocus rates FRA:Q8T with a GF Score™ of 96/100 and a GF Value™ of €0.48. The stock has 2 warning signs investors should review. Among 759 Medical Devices & Instruments companies, OrbusNeich Medical Group Holdings ranks better than 69.04% on this metric.
The historical rank and industry rank for OrbusNeich Medical Group Holdings's Return-on-Tangible-Equity or its related term are showing as below:
FRA:Q8T'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -4.35 Med: 11.05 Max: 13.7
Current: 11.01
During the past 7 years, OrbusNeich Medical Group Holdings's highest Return-on-Tangible-Equity was 13.70%. The lowest was -4.35%. And the median was 11.05%.
FRA:Q8T's Return-on-Tangible-Equity is ranked better than 69.04% of 759
companies
in the Medical Devices & Instruments industry
Industry Median: 4.04
vs FRA:Q8T: 11.01
OrbusNeich Medical Group Holdings (FRA:Q8T) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
OrbusNeich Medical Group Holdings Return-on-Tangible-Equity Related Terms
OrbusNeich Medical Group Holdings Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OrbusNeich Medical Group Holdings Return-on-Tangible-Equity Chart
FRA:Q8T vs ISRG, BDX, MDLN: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, OrbusNeich Medical Group Holdings's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OrbusNeich Medical Group Holdings Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, OrbusNeich Medical Group Holdings's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where OrbusNeich Medical Group Holdings's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 11.36% mean?
OrbusNeich Medical Group Holdings (FRA:Q8T) has a Return-on-Tangible-Equity of 11.36% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on OrbusNeich Medical Group Holdings and its competitors. This is near median its historical median of 11.05. According to the industry distribution chart, OrbusNeich Medical Group Holdings ranks #235 out of 759 companies in the Medical Devices & Instruments industry, placing it in the top 31%.
Is OrbusNeich Medical Group Holdings' Return-on-Tangible-Equity too high?
OrbusNeich Medical Group Holdings' current Return-on-Tangible-Equity of 11.36% is near median its 10-year median of 11.05. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.04. OrbusNeich Medical Group Holdings' value of 11.36% is 181.2% above this industry median. Based on the distribution chart, OrbusNeich Medical Group Holdings ranks #235 out of 759 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, OrbusNeich Medical Group Holdings has a GF Score™ of 96/100, reflecting its overall financial health beyond just this single metric.
How does OrbusNeich Medical Group Holdings' Return-on-Tangible-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, OrbusNeich Medical Group Holdings ranks #235 out of 759 companies for Return-on-Tangible-Equity. This puts OrbusNeich Medical Group Holdings in the upper half of its industry. The industry median Return-on-Tangible-Equity is 4.04. OrbusNeich Medical Group Holdings' value of 11.36% is 181.2% above this benchmark. While the company's 10-year median is 11.05 vs. the industry median of 4.04, OrbusNeich Medical Group Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.04, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OrbusNeich Medical Group Holdings's current Return-on-Tangible-Equity of 11.36% is 181.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on OrbusNeich Medical Group Holdings and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OrbusNeich Medical Group Holdings's current Return-on-Tangible-Equity is 11.36%, which is near median its own 10-year median of 11.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OrbusNeich Medical Group Holdings stock overvalued right now?
OrbusNeich Medical Group Holdings (FRA:Q8T) has a current Return-on-Tangible-Equity of 11.36%. The stock's GF Value™ is €0.48, compared to a current price of €0.33 — trading 30.4% below its estimated fair value. The current Return-on-Tangible-Equity is 11.36%, which is near median its 10-year median of 11.05 and 181.2% above the Medical Devices & Instruments industry median of 4.04. OrbusNeich Medical Group Holdings' overall GF Score™ is 96/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For OrbusNeich Medical Group Holdings (FRA:Q8T), the current Return-on-Tangible-Equity is 11.36% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OrbusNeich Medical Group Holdings (FRA:Q8T) Overvalued in 2026?
Based on GuruFocus' analysis, OrbusNeich Medical Group Holdings stock appears to be undervalued.
The current stock price of €0.33 is trading 30.4% below its estimated GF Value™ of €0.48.
Key valuation signals for FRA:Q8T:
Return-on-Tangible-Equity: 11.36% (near median its 10-year median of 11.05)
GF Value™: €0.48 vs. price of €0.33 (30.4% below fair value)
Industry Position: 181.2% above the Medical Devices & Instruments median (#235 of 759)
No single metric tells the full story. See the FRA:Q8T stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OrbusNeich Medical Group Holdings Business Description
OrbusNeich Medical Group Holdings Ltd is an investment holding company. The Company principally engaged in the manufacturing, trading, sales and marketing of medical devices/instruments used for the treatment of coronary and peripheral vascular diseases. The group has only one operating segment. The company has presence in APAC, EMEA, Japan, United States, The PRC, and Others of which majority of revenue comes from APAC.
96GF Score
Get the complete analysis for FRA:Q8T
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:Q8T has been successfully added to your 
